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CELL PROLIFERATION
The ROCKs on which tumour
cells thrive
A new study reveals that the ROCK proteins play key roles in the
formation of tumours in mice.
SIMON WILKINSON AND MARGARET C FRAME
A
family of signalling proteins called the
Rho GTPases are known to have a
profound influence on the formation of
tumours in humans and other animals. Once
activated, Rho GTPases bind to and activate
a network of other proteins in cells, including
the enzymes ROCK1 and ROCK2 (Rho-associ-
ated, coiled-coil-containing protein kinases;
Riento and Ridley, 2003). Now, in eLife, Sandra
Ku¨mper of the Institute of Cancer Research (ICR)
and colleagues – including the late Christopher
Marshall – report that ROCK activity is essential
for tumours to form in mice (Ku¨mper et al.,
2016).
Cells contain networks of filaments made of a
protein called F-actin and the ROCK proteins
target other proteins that regulate the accumu-
lation of F-actin. They also regulate the activity
of a motor protein called myosin II, which gener-
ates the forces that drive the contraction of F-
actin via a process called “actomyosin contractil-
ity”. This process is critical for, among other
things, muscle contraction and the migration of
cells around the body.
In part due to two decades of insightful work
by Christopher Marshall and various colleagues,
it is now accepted that the ROCKs (Sahai and
Marshall, 2003) and related kinases (such as the
MRCKs; Wilkinson et al., 2005) have key roles
in the migration of tumour cells (Sadok et al.,
2015). Changes in actomyosin contractility are
involved in these migrations, which are responsi-
ble for the spread of cancer around the body.
Moreover, recent studies show that ROCK1/2
also have other roles in cell division and in pro-
moting tumour growth (Samuel et al., 2011;
Kumar et al., 2012).
However, we do not fully understand how the
ROCK proteins regulate actomyosin contractility
and cancer cell division, or if these phenomena
are linked. These are particularly pertinent ques-
tions given that clinical trials are underway to
test whether some drugs that inhibit the ROCK
proteins could be used to treat cancer.
Ku¨mper et al. – who are based at the ICR and
Cancer Research UK institutes in London and
Manchester – set out to address these questions
using mice that carried “conditional” alleles of
the genes that encode ROCK1 and/or ROCK2.
This made it possible for the team to selectively
delete these genes without affecting animal
development. First, they isolated fibroblast cells
from mouse embryos and created sublines of
cells that were unable to produce one or both
ROCK proteins. The loss of either ROCK protein
alone had no effect on the cells, but the loss of
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both suppressed actomyosin contractility and
stopped the cells from dividing (Figure 1).
A drug called Blebbistatin, which inhibits
the activity of myosin II, also suppressed cell
division. Strikingly, the loss of division in both
the cells from the conditional mice and those
treated with Blebbistatin was linked to the acti-
vation of a new form of cellular senescence,
the process by which cells permanently stop
dividing (Figure 1). Proteomic analyses
revealed that this senescence was hallmarked
by specific reductions in the levels of particular
cell-cycle proteins. Unusually, this form of
senescence did not rely on a key protein
that is usually involved in such responses, the
tumour suppressor p53.
Figure 1. ROCK proteins and the cell cycle. ROCK1 and ROCK2 help cells to divide by enabling a process called
actomyosin contractility (left). This process also promotes the production of three proteins (CDK1, CyclinA and
CKS1) that have an important role in causing cells to increase in number (proliferate). These proteins drive the cell
cycle that underpins the proliferation of both normal and cancerous cells: DNA replication occurs in stage S of the
cycle, with cell division taking place in stage G2/M. Ku¨mper et al. found that the loss of both ROCK genes, or the
use of drugs that inhibit ROCK activity, can permanently stop mouse cells from dividing (right). This phenomenon,
which is known as cellular senescence, is probably caused by the loss of actomyosin contractility, which leads to
lower levels of CDK1, CyclinA and CKS1.
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The above data are exciting because they
imply that sustained activity of either ROCK1 or
ROCK2 – and the resulting actomyosin contrac-
tility – is sufficient to allow cultured cells to con-
tinue to divide past the point where they would
usually enter senescence. Senescence is also
emerging as a major barrier to the formation
and growth of tumours in the body: so, does this
mean that ROCK proteins are also redundant in
tumour formation?
To address this question, Ku¨mper et al. gen-
erated cancerous forms of fibroblast cells from
the embryos of ROCK conditional mice. The abil-
ity of these cells to form tumours was tested by
xenografting the cells onto “nude” mice that
lack the immune responses that usually protect
mice from tumours. The presence of either
ROCK1 or ROCK2 was sufficient to support
tumour growth, but tumours did not form if
both were missing.
Cross-breeding the conditional mice to other
mice that were genetically engineered to
develop lung cancer showed that the presence
of either ROCK1 or ROCK2 alone was sufficient
to allow tumour cells to divide. However, the
loss of a single ROCK protein alone did have
some subtle (and as yet unexplained) effects on
cell division. Importantly, Ku¨mper et al. never
found any tumours that developed without one
or other ROCK protein being expressed, which
is consistent with the findings of the xenografted
cell line experiments.
An outstanding question is whether the cell
senescence phenotype observed in the cell lines
would also be seen in the animal. Ku¨mper et al.
found that treating mice with a drug called
AT13148 – which inhibits both ROCK1 and
ROCK2 (Sadok et al., 2015) – could induce the
senescence of skin cancer cells that had been
grafted into mice. This suggests that it is possible
to induce senescence in tumour cells in an animal
by targeting the activity of the ROCK proteins.
This finding is also consistent with emerging evi-
dence that ROCK inhibitors may have anti-tumour
effects (Kumar et al., 2012; Smit et al., 2014).
This study extends our understanding of small
GTPase signalling pathways and how they con-
tribute to the formation of tumours.
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